Sensei Biotherapeutics Inc (SNSE)

$10.56 +0.10 (0.96%)
Market Cap 13.19M
Revenue (ttm) 0.00
Net Income (ttm) -30.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,000
Avg Vol 29,868
Day's Range N/A - N/A
Shares Out 1.26M
Stochastic %K 7%
Beta 0.31
Analysts Strong Sell
Price Target $32.50

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 243 8000
Address:
1405 Research Boulevard, Suite 125, Rockville, United States
DaBullRunner
DaBullRunner Oct. 23 at 3:42 PM
$ARMP $SNSE MARK MY WORDS One of these two could pull a $SPRB type move🚨 $SCNX $BYND like I said know these things👇
3 · Reply
Mike93
Mike93 Oct. 22 at 7:50 PM
$SNSE low floater trading under cash
0 · Reply
nonamed
nonamed Oct. 21 at 5:40 PM
Wow the board is dead $SNSE
0 · Reply
rrc2007
rrc2007 Oct. 20 at 5:12 PM
$SNSE
0 · Reply
ffeng23
ffeng23 Oct. 20 at 3:47 AM
$SNSE their data seem pretty good imo. #unalloyed
0 · Reply
Unalloyed
Unalloyed Oct. 19 at 8:32 PM
$SNSE Stock falls after bad data https://www.investing.com/news/stock-market-news/sensei-biotherapeutics-stock-falls-after-phase-12-trial-results-93CH-4294792
1 · Reply
Unalloyed
Unalloyed Oct. 19 at 8:30 PM
$SNSE
0 · Reply
dbr_island
dbr_island Oct. 17 at 10:52 PM
$SNSE could be the next $SPRB is what my gut tells me RVP starting a position from some of my TSLA holdings Here’s why👇🚨🚨🚨
0 · Reply
dbr_island
dbr_island Oct. 17 at 10:07 PM
$SNSE watching very closely… that news was very solid folks RVP starting a position from some of my TSLA holdings Here’s why👇🚨🚨🚨
0 · Reply
Mr_Gambino
Mr_Gambino Oct. 17 at 9:44 PM
$SNSE failed data, it was a pump and dump lol i'm surprised they never usually disclose the bad news
1 · Reply
Latest News on SNSE
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Oct 17, 2025, 8:00 AM EDT - 8 days ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 23, 2025, 7:30 AM EDT - 4 weeks ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jul 30, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Jun 13, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 2, 2025, 7:30 AM EDT - 7 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 28, 2025, 7:30 AM EDT - 7 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Mar 27, 2025, 4:05 PM EDT - 7 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 9 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Jan 8, 2025, 7:30 AM EST - 10 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 4:05 PM EST - 11 months ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Upcoming Conferences

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Mar 7, 2023, 5:15 PM EST - 2 years ago

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Mar 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

DaBullRunner
DaBullRunner Oct. 23 at 3:42 PM
$ARMP $SNSE MARK MY WORDS One of these two could pull a $SPRB type move🚨 $SCNX $BYND like I said know these things👇
3 · Reply
Mike93
Mike93 Oct. 22 at 7:50 PM
$SNSE low floater trading under cash
0 · Reply
nonamed
nonamed Oct. 21 at 5:40 PM
Wow the board is dead $SNSE
0 · Reply
rrc2007
rrc2007 Oct. 20 at 5:12 PM
$SNSE
0 · Reply
ffeng23
ffeng23 Oct. 20 at 3:47 AM
$SNSE their data seem pretty good imo. #unalloyed
0 · Reply
Unalloyed
Unalloyed Oct. 19 at 8:32 PM
$SNSE Stock falls after bad data https://www.investing.com/news/stock-market-news/sensei-biotherapeutics-stock-falls-after-phase-12-trial-results-93CH-4294792
1 · Reply
Unalloyed
Unalloyed Oct. 19 at 8:30 PM
$SNSE
0 · Reply
dbr_island
dbr_island Oct. 17 at 10:52 PM
$SNSE could be the next $SPRB is what my gut tells me RVP starting a position from some of my TSLA holdings Here’s why👇🚨🚨🚨
0 · Reply
dbr_island
dbr_island Oct. 17 at 10:07 PM
$SNSE watching very closely… that news was very solid folks RVP starting a position from some of my TSLA holdings Here’s why👇🚨🚨🚨
0 · Reply
Mr_Gambino
Mr_Gambino Oct. 17 at 9:44 PM
$SNSE failed data, it was a pump and dump lol i'm surprised they never usually disclose the bad news
1 · Reply
dbr_island
dbr_island Oct. 17 at 9:16 PM
$RVP starting a position from some of my TSLA holdings Here’s why👇🚨🚨🚨 $TGHL $STKE $FGI $SNSE watching closely
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 17 at 9:01 PM
All eyes on VRME the next potential super stock , $1 to $10🚨 $OPEN $RR $SPRB $SNSE
0 · Reply
wisdom_trade
wisdom_trade Oct. 17 at 7:55 PM
$SNSE company make up fase data
0 · Reply
wisdom_trade
wisdom_trade Oct. 17 at 7:54 PM
$SNSE faild FDA data
0 · Reply
Logan12071
Logan12071 Oct. 17 at 7:15 PM
$SNSE this charts either going big or going home at close.
1 · Reply
AriyahPerez
AriyahPerez Oct. 17 at 5:38 PM
$SNSE Price points in IVD are resilient the difference between $95 and $125 per kit looks small but at 20k units it is a $0.6M delta and gross profit can step up by 6 to 8 points when manufacturing and logistics consolidate to 2 or 3 hubs
0 · Reply
ikkydiphoenix
ikkydiphoenix Oct. 17 at 4:42 PM
$SNSE after so many years anyday i still see new things never seen before, as the movements of this one today eh
0 · Reply
theSnip3r
theSnip3r Oct. 17 at 3:57 PM
$SNSE just get it back to $13 break even already
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Oct. 17 at 3:32 PM
$SNSE another shit play from moonmarket
0 · Reply
Mr_Gambino
Mr_Gambino Oct. 17 at 3:15 PM
$SNSE you must be getting your alerts from internet explorer cuz if your buying here you're like 2 days late, it's time to sell and move on kid.
0 · Reply
Habib1234
Habib1234 Oct. 17 at 3:14 PM
$SNSE 👀
0 · Reply
Habib1234
Habib1234 Oct. 17 at 3:08 PM
$SNSE 15
1 · Reply